Your browser doesn't support javascript.
loading
Clinical Features and Survival of Patients With Follicular Lymphoma in Korea.
Cho, Su-Hee; Suh, Cheolwon; Do, Young Rok; Lee, Je-Jung; Yun, Hwan-Jung; Oh, Sung Young; Lee, Ho Sup; Cho, Seok-Goo; Cho, In Sung; Lee, Won-Sik; Won, Young-Woong; Kim, Hyo Jung; Lee, Hong Ghi; Lee, Soon Il; Lim, Sung-Nam; Sohn, Byeong Seok; Ahn, Heui June; Chang, Myung Hee; Kwon, Kyung A; Kim, Won Seog.
Afiliação
  • Cho SH; Division of Hematology-Oncology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, South Korea.
  • Suh C; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Do YR; Department of Hematology-Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea.
  • Lee JJ; Department of Hematology, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
  • Yun HJ; Division of Hematology-Oncology, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, South Korea.
  • Oh SY; Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea.
  • Lee HS; Division of Hematology-Oncology, Department of Internal Medicine, Kosin University Gospel Hospital, Busan, South Korea.
  • Cho SG; Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
  • Cho IS; Division of Hematology-Oncology, Department of Internal Medicine, Eulji University Hospital, Daejeon, South Korea.
  • Lee WS; Department of Hematology-Oncology, Inje University College of Medicine, Busan Paik Hospital, Busan, South Korea.
  • Won YW; Division of Hematology-Oncology, Department of Internal Medicine, Hanyang University College of Medicine, Guri, South Korea.
  • Kim HJ; Division of Hematology-Oncology, Department of Internal Medicine, College of Medicine, Hallym University, Hallym University Sacred Heart Hospital, Anyang, South Korea.
  • Lee HG; Division of Hematology-Oncology, Department of Internal Medicine, Konkuk University Medical Center, Seoul, South Korea.
  • Lee SI; Division of Hematology-Oncology, Department of Internal Medicine, Dankook University Hospital, Cheonan, South Korea.
  • Lim SN; Department of Hematology-Oncology, Inje University College of Medicine, Busan Hae-undae Paik Hospital, Busan, South Korea.
  • Sohn BS; Department of Hematology-Oncology, Inje University College of Medicine, Sanggye Paik Hospital, Seoul, South Korea.
  • Ahn HJ; Department of Oncology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea.
  • Chang MH; Department of Hematology-Oncology, Ilsan Hospital, Goyang, South Korea.
  • Kwon KA; Division of Hematology-Oncology, Department of Internal Medicine, Dongnam Institute of Radiological and Medical Sciences, Busan, South Korea.
  • Kim WS; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Electronic address: wskimsmc@skku.edu.
Clin Lymphoma Myeloma Leuk ; 16(4): 197-202, 2016 Apr.
Article em En | MEDLINE | ID: mdl-26850215
ABSTRACT

BACKGROUND:

The incidence of follicular lymphoma (FL) varies according to geographic location. It is the second most common non-Hodgkin lymphoma in Western countries but has a very low incidence in Asia. Thus, no representative data are available for FL. Therefore, we gathered our own data to build a foundation for FL research. PATIENTS AND

METHODS:

We collected a total of 343 patient records. The median age was 53 years, and the ratio of male to female patients was 1.41. Most patients received chemotherapy with or without rituximab.

RESULTS:

The incidence of grade 1 and 2 FL was 64.9% (n = 205) and of stage III and IV was 51.2% (n = 171). The grade tended to be higher and the stage to be lower compared with Western data. In the chemotherapy group, the complete response rate was 76.0%, and the partial response rate was 17.1%. The median follow-up duration was 38.1 months. The estimated 5- and 10-year progression-free survival and overall survival rates were 68.3% and 84.9% and 63.0% and 71.3%, respectively.

CONCLUSION:

We could not find definitive differences between our Korean data and the Western data, although we found some trends in the baseline characteristics. Therefore, we hope to develop an understanding of FL and perform more qualitative studies in the future.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Folicular Tipo de estudo: Incidence_studies / Prognostic_studies / Qualitative_research Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Clin Lymphoma Myeloma Leuk Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Coréia do Sul

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Folicular Tipo de estudo: Incidence_studies / Prognostic_studies / Qualitative_research Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Clin Lymphoma Myeloma Leuk Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Coréia do Sul